Cormorant Asset Management as of Sept. 30, 2020
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 90 positions in its portfolio as reported in the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Turning Point Therapeutics I | 8.2 | $213M | 2.4M | 87.36 | |
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 6.4 | $167M | 500k | 334.89 | |
| Forma Therapeutics Hldgs SHS | 6.4 | $167M | 3.4M | 49.26 | |
| Revolution Medicines (RVMD) | 3.5 | $92M | 2.6M | 34.80 | |
| Chemocentryx | 3.5 | $90M | 1.7M | 54.80 | |
| Bridgebio Pharma (BBIO) | 3.3 | $85M | 2.3M | 37.52 | |
| Ishares Tr Russell 2000 Etf Put Option (IWM) | 2.9 | $75M | 500k | 149.79 | |
| Sorrento Therapeutics Com New (SRNE) | 2.8 | $73M | 6.5M | 11.15 | |
| Avidity Biosciences Ord (RNA) | 2.7 | $70M | 2.5M | 27.65 | |
| Myokardia | 2.4 | $61M | 450k | 136.33 | |
| Omeros Corporation (OMER) | 2.3 | $61M | 6.0M | 10.11 | |
| Immunovant (IMVT) | 2.2 | $58M | 1.6M | 35.19 | |
| Apellis Pharmaceuticals (APLS) | 2.2 | $56M | 1.9M | 30.17 | |
| Acceleron Pharma | 2.2 | $56M | 500k | 112.53 | |
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 2.1 | $56M | 500k | 111.43 | |
| Y Mabs Therapeutics (YMAB) | 2.1 | $54M | 1.4M | 38.39 | |
| Zymeworks | 2.1 | $54M | 1.2M | 46.58 | |
| Stoke Therapeutics (STOK) | 2.0 | $52M | 1.5M | 33.49 | |
| Eidos Therapeutics | 1.9 | $50M | 993k | 50.53 | |
| Mirati Therapeutics | 1.8 | $46M | 275k | 166.05 | |
| Viela Bio | 1.7 | $45M | 1.6M | 28.08 | |
| Reata Pharmaceuticals Cl A | 1.7 | $44M | 450k | 97.42 | |
| Twist Bioscience Corp (TWST) | 1.5 | $38M | 500k | 75.97 | |
| Alx Oncology Hldgs (ALXO) | 1.4 | $36M | 972k | 37.00 | |
| Trillium Therapeutics Com New | 1.4 | $36M | 2.5M | 14.21 | |
| Axonics Modulation Technolog (AXNX) | 1.4 | $35M | 693k | 51.04 | |
| Agenus Com New | 1.3 | $34M | 8.5M | 4.00 | |
| Biohaven Pharmaceutical Holding | 1.2 | $33M | 500k | 65.01 | |
| Rocket Pharmaceuticals (RCKT) | 1.2 | $31M | 1.4M | 22.86 | |
| Arcturus Therapeutics Hldg I (ARCT) | 1.2 | $30M | 700k | 42.90 | |
| Myovant Sciences | 1.2 | $30M | 2.1M | 14.05 | |
| Akero Therapeutics (AKRO) | 1.0 | $27M | 860k | 30.79 | |
| Blueprint Medicines (BPMC) | 1.0 | $26M | 275k | 92.70 | |
| Crispr Therapeutics Namen Akt (CRSP) | 1.0 | $25M | 300k | 83.64 | |
| Albireo Pharma | 0.9 | $23M | 700k | 33.37 | |
| Biontech Se Sponsored Ads (BNTX) | 0.9 | $22M | 325k | 68.95 | |
| Cabaletta Bio (CABA) | 0.9 | $22M | 2.1M | 10.84 | |
| Beam Therapeutics (BEAM) | 0.8 | $20M | 796k | 24.62 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.7 | $19M | 125k | 154.32 | |
| Galapagos Nv Spon Adr (GLPG) | 0.7 | $19M | 130k | 142.08 | |
| Axsome Therapeutics (AXSM) | 0.7 | $18M | 250k | 71.25 | |
| Igm Biosciences (IGMS) | 0.6 | $17M | 225k | 73.81 | |
| Zai Lab Adr (ZLAB) | 0.6 | $16M | 189k | 83.17 | |
| Inspire Med Sys (INSP) | 0.6 | $16M | 120k | 129.05 | |
| Kura Oncology (KURA) | 0.6 | $15M | 500k | 30.64 | |
| Pliant Therapeutics (PLRX) | 0.5 | $14M | 611k | 22.20 | |
| Otonomy | 0.5 | $13M | 3.2M | 4.05 | |
| Deciphera Pharmaceuticals | 0.5 | $13M | 250k | 51.30 | |
| Tcr2 Therapeutics Inc cs | 0.5 | $12M | 600k | 20.32 | |
| Uniqure Nv SHS (QURE) | 0.5 | $12M | 325k | 36.83 | |
| Sarepta Therapeutics (SRPT) | 0.5 | $12M | 85k | 140.44 | |
| Insmed Com Par $.01 (INSM) | 0.4 | $11M | 350k | 32.14 | |
| Akouos | 0.4 | $11M | 500k | 22.41 | |
| Repare Therapeutics Ord (RPTX) | 0.4 | $11M | 349k | 30.77 | |
| Argenx Se Sponsored Adr (ARGX) | 0.4 | $11M | 40k | 262.52 | |
| Quotient SHS | 0.4 | $10M | 2.0M | 5.14 | |
| Harpoon Therapeutics | 0.4 | $9.7M | 571k | 16.99 | |
| Theravance Biopharma (TBPH) | 0.4 | $9.6M | 650k | 14.78 | |
| Anaptysbio Inc Common (ANAB) | 0.4 | $9.6M | 650k | 14.75 | |
| Health Sciences Acq Corp 2 Ord Shs | 0.3 | $8.8M | 800k | 11.00 | |
| Iteos Therapeutics (ITOS) | 0.3 | $8.6M | 350k | 24.67 | |
| Bctg Acquisition Corp | 0.3 | $8.4M | 800k | 10.46 | |
| Protara Therapeutic Com Stk (TARA) | 0.3 | $7.6M | 450k | 16.83 | |
| Therapeutics Acquisition Cor Com Cl A | 0.3 | $7.2M | 500k | 14.38 | |
| Morphic Hldg (MORF) | 0.3 | $6.8M | 250k | 27.34 | |
| Tricida | 0.3 | $6.6M | 728k | 9.06 | |
| Allakos (ALLK) | 0.2 | $6.1M | 75k | 81.45 | |
| Genetron Hldgs Ads | 0.2 | $6.0M | 500k | 11.94 | |
| Aveo Pharmaceuticals Com New | 0.2 | $5.9M | 1.0M | 5.94 | |
| Fs Dev Corp Com Cl A | 0.2 | $5.6M | 500k | 11.20 | |
| Merus N V (MRUS) | 0.2 | $5.2M | 429k | 12.00 | |
| Homology Medicines | 0.2 | $5.0M | 471k | 10.70 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $4.9M | 422k | 11.64 | |
| Kezar Life Sciences | 0.2 | $4.5M | 932k | 4.84 | |
| Vesper Healthcare Acqstn Cor Unit 99/99/9999 | 0.2 | $4.1M | 400k | 10.26 | |
| Atreca Cl A Com (BCEL) | 0.2 | $4.1M | 294k | 13.97 | |
| Kadmon Hldgs | 0.2 | $3.9M | 1.0M | 3.92 | |
| Eiger Biopharmaceuticals | 0.1 | $3.7M | 450k | 8.14 | |
| Avrobio Ord (AVRO) | 0.1 | $3.2M | 244k | 13.02 | |
| Gossamer Bio (GOSS) | 0.1 | $3.1M | 248k | 12.41 | |
| Panacea Acquisition Corp Unit 99/99/9999 | 0.1 | $3.0M | 250k | 12.00 | |
| Cardiff Oncology (CRDF) | 0.1 | $2.5M | 175k | 14.19 | |
| Arena Pharmaceuticals Com New | 0.1 | $2.2M | 30k | 74.80 | |
| Precision Biosciences Ord | 0.1 | $2.1M | 347k | 6.16 | |
| Amarin Corp Spons Adr New (AMRN) | 0.0 | $1.3M | 300k | 4.21 | |
| Orchard Therapeutics Ads | 0.0 | $1.1M | 257k | 4.11 | |
| Nektar Therapeutics (NKTR) | 0.0 | $830k | 50k | 16.60 | |
| Minerva Neurosciences | 0.0 | $759k | 239k | 3.18 | |
| Fate Therapeutics (FATE) | 0.0 | $600k | 15k | 40.00 | |
| Outlook Therapeutics *w Exp 02/18/202 | 0.0 | $54k | 417k | 0.13 |
